Targeted therapies: Sunitinib versus interferon-α in metastatic RCC

Nature Reviews Clinical Oncology

Volumn 7, Issue 1, 2010, Pages 7-8

  Faris, Jason E ^a   Michaelson, M Dror ^a  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ALPHA INTERFERON; BEVACIZUMAB; CALCIUM; EVEROLIMUS; HEMOGLOBIN; LACTATE DEHYDROGENASE; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

CANCER RESEARCH; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG APPROVAL; DRUG SAFETY; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HUMAN; INDIVIDUALIZATION; KIDNEY CARCINOMA; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT CARE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK ASSESSMENT; SHORT SURVEY; TREATMENT OUTCOME;

EID: 76849102403     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2009.173     Document Type: Short Survey

References (10)

1. Motzer, R. J. et al. sunitinib efficacy against advanced renal cell carcinoma. J. Urol. 178, 1883-1887 (2007).
2. Motzer, R. J. et al. sunitinib versus interferon alfa in metastatic renal cell carcinoma. N. Engl. J. Med. 356, 115-124 (2007).
3. Motzer, R. J. et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 3584-3590 (2009).
4. escudier, B. et al. sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase iii treatment approaches in renal cancer global evaluation trial. J. Clin. Oncol. 27, 3312-3318 (2009).
5. Motzer, R. J. et al. efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase iii trial. Lancet 327, 449-456 (2008).
6. escudier, B. et al. Bevacizumab plus interferon-?2a for treatment ofmetastatic renal cell carcinoma: a randomised, doubleblind phase iii trial. Lancet 370, 2103-2111 (2008).
7. Rini, B. i. et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J. Clin. Oncol. 26, 5422-5428 (2008).
8. Hudes, G. R. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271-2281 (2007).
9. Gore, M. e. et al. safety and efficacy of sunitinib for metastatic renal cell carcinoma: an expanded-access trial. Lancet 10, 757-763 (2009).
10. Iliopoulos, O. et al. negative regulation of hypoxia-inducible genes by the von Hippel- Lindau protein. Proc. Natl Acad. Sci. USA 93, 10595-10599 (1996).